Trial Profile
Comparison of Biomatrix and Orsiro Drug Eluting Stent in Angiographic Result in Patients With All-comer Patients With Coronary Artery Disease : A Multicenter, Randomized, Open Label Study (BIODEGRADE Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Sep 2019
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Umirolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms BIODEGRADE
- 23 Sep 2019 Status changed from recruiting to completed.
- 28 Nov 2014 New trial record